One-glance verdict
Within fair range
$19.41 our estimate vs market $19.75
Wall Street consensus: $19.83 (2.2% higher than our fair-value estimate)
2% above our estimate
Fundamentals snapshot
Kenvue Inc.
KVUE · NYQ · Consumer Defensive · Household & Personal Products
Current price
$19.75
52-week range
$14.02 - $22.44
Market cap
$37.92B
Balance sheet
Watch
6.31x Adequate
Net debt $7.73B. Interest coverage shows how many times profit covers the interest bill.
What stands out
3 Rewards
1 Risk
3 rewards · 1 risks
- Reward Revenue grew 1.1% last year.
- Reward Returns 15.7% on equity, ahead of 20% of its peers.
- Reward Free cash flow was positive in 4/10 years.
- Risk Insider ownership is only 0.1% (peer median: 0.2%).
What this company does
Kenvue Inc.
Kenvue is the company behind many famous household brands you likely have in your medicine cabinet, such as Tylenol, Band-Aid, Neutrogena, and Listerine. It makes money selling these everyday consumer health products, which are split into three main areas: over-the-counter medicines, skin and beauty care, and essential items like baby products and mouthwash. Because these are trusted products people often buy repeatedly regardless of how the economy is doing, the company's sales tend to be relatively stable over time.
How the company got here
Kenvue is a new name for a collection of very old, well-known brands. It was formerly the consumer health division of the healthcare giant Johnson & Johnson. In 2021, Johnson & Johnson announced it would spin off this division to create a new, separate company focused entirely on everyday consumer health products. This separation, which was completed in 2023, allows both Kenvue and its former parent to focus more on their specific areas – everyday consumer products for Kenvue, and pharmaceuticals and medical devices for Johnson & Johnson. The name 'Kenvue' is a combination of 'ken', a Scottish word for knowledge, and 'vue', for sight or insight.
What it actually does
Kenvue makes and sells a wide range of health and personal care products that you can find in most drugstores and supermarkets. These are everyday items that people use to take care of themselves and their families, from pain relievers and allergy medicines to skin and hair care products. Think of brands like Tylenol for headaches, Band-Aid for cuts, Listerine for oral hygiene, and Neutrogena for skin care. The company's products are generally things you can buy without a prescription to manage common health and wellness needs.
Self Care
This is Kenvue's largest business segment and includes many of its most recognizable over-the-counter medicines. When you buy Tylenol or Motrin for pain relief, Zyrtec or Benadryl for allergies, or Nicorette to stop smoking, you are buying from Kenvue's Self Care division. This segment focuses on products that help people treat common ailments themselves. It represents the biggest piece of the company's sales.
Skin Health and Beauty
This part of the company focuses on products for your skin and hair. It includes well-known brands like Neutrogena, Aveeno, and OGX. Whether it's a face wash, a daily moisturizer, sunscreen, or shampoo, these products are all part of the Skin Health and Beauty segment. This segment aims to offer science-backed products for various skin and hair needs, from acne treatment to daily hydration.
Essential Health
This segment covers a variety of daily hygiene and health products. It includes iconic brands like Band-Aid for wound care, Listerine for oral care, and Johnson's for baby care. Products for women's health and other essential daily needs also fall into this category. These are often staple items that households purchase regularly for their basic health and hygiene routines.
What management is betting on now
Since becoming a standalone company, Kenvue's management is focused on improving its operations and growing its well-known brands. A key priority is to become more efficient and cut costs, with a goal of saving hundreds of millions of dollars to improve its profitability, often measured by things like EBITDA margin (a way to look at a company's profitability from its core operations). The company is also investing more in marketing for its top brands and expanding its sales online and in international markets. Additionally, Kenvue is focused on sustainability, with goals to reduce its carbon emissions and make its packaging more recyclable.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q2
$350.00M
FY2024 Q3
$190.00M
FY2024 Q4
$661.00M
FY2025 Q1
$249.00M
FY2025 Q2
$533.00M
FY2025 Q3
$196.00M
FY2025 Q4
$744.00M
FY2026 Q1
$350.00M
Revenue
$3.91B
Net income
$474.00M
Diluted EPS
0.25
Operating cash flow
$489.00M
Free cash flow
$350.00M
Fetching…
Sources
Revenue
$3.78B
Net income
$330.00M
Diluted EPS
0.16
Operating cash flow
$854.00M
Free cash flow
$744.00M
Fetching…
Sources
Revenue
$3.76B
Net income
$398.00M
Diluted EPS
0.21
Operating cash flow
$294.00M
Free cash flow
$196.00M
Fetching…
Sources
Revenue
$3.84B
Net income
$420.00M
Diluted EPS
0.22
Operating cash flow
$621.00M
Free cash flow
$533.00M
Fetching…
Sources
Revenue
$3.74B
Net income
$322.00M
Diluted EPS
0.17
Operating cash flow
$428.00M
Free cash flow
$249.00M
Fetching…
Sources
Revenue
$3.66B
Net income
$293.00M
Diluted EPS
0.16
Operating cash flow
$793.00M
Free cash flow
$661.00M
Fetching…
Sources
Revenue
$3.90B
Net income
$383.00M
Diluted EPS
0.20
Operating cash flow
$249.00M
Free cash flow
$190.00M
Fetching…
Sources
Revenue
$4.00B
Net income
$58.00M
Diluted EPS
0.03
Operating cash flow
$440.00M
Free cash flow
$350.00M
Fetching…
Sources
Is it cheap or expensive?
Fair value $19.41 vs current price $19.75
Wall Street consensus is the average analyst price target: $19.83 (2.2% higher than our fair-value estimate).
Our most-likely fair value is $19.41 a share — about 1.7% away from today's price of $19.75, so the stock currently looks fairly priced.
Is it drowning in debt?
Watch
Net debt $7.7B. Interest coverage 6.3x.
Net debt
$7.73B
Interest coverage
6.31x
Kenvue Inc.'s profit covers its interest bill about 6.3 times over. which is weaker than most peers shown here.
Watch
Worse cushion
Baseline
Better cushion
KVUE
BASELINE
Kenvue Inc.
Total debt $8.80B Interest coverage 6.31x This is the baseline the peer rows are being compared against.
Total debt $11.48B Interest coverage 6.95x +10% vs KVUE Has roughly the same debt cushion as KVUE.
Total debt $7.11B Interest coverage 9.18x +45% vs KVUE Carries about 1.5x more debt cushion than KVUE.
Total debt $7.97B Interest coverage 15.85x +151% vs KVUE Carries about 2.5x more debt cushion than KVUE.
Total debt $2.38B Interest coverage 11.32x +79% vs KVUE Carries about 1.8x more debt cushion than KVUE.
What you should know
The case for and against KVUE
3 Rewards
1 Risk
Rewards
-
Revenue grew 1.1% last year.
-
Returns 15.7% on equity, ahead of 20% of its peers.
-
Free cash flow was positive in 4/10 years.
Risks
-
Insider ownership is only 0.1% (peer median: 0.2%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
23.51x
Forward P/E
15.91x
P/B
3.57x
P/S
2.48x
EV/EBITDA
13.01x
PEG ratio
1.60x
Profitability
How much profit each dollar creates
Gross margin
58.6%
Operating margin
21.6%
Net margin
10.6%
ROE
15.7%
ROA
7.1%
Health
Liquidity and balance-sheet strength
Debt / equity
0.83x
Current ratio
0.98x
Quick ratio
0.61x
Total debt
$8.80B
Total cash
$1.08B
Growth
How the business has been compounding
Revenue TTM
$15.29B
Revenue 5Y CAGR
-1.0%
EPS TTM
0.84
EPS 5Y CAGR
-11.4%
Cash flow
How much cash the business throws off
Operating CF TTM
$2.26B
Free CF TTM
$1.72B
FCF margin
11.3%
Dividend
Shareholder payout
Yield
4.3%
Payout ratio
98.5%
Last ex-div date
2026-05-13